Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Register of interests (PDF 291 KB)

Final draft guidance: TA872

Final appraisal document (PDF 249 KB)

Public committee slides ACM1 Slides (PDF 965 KB)

Public committee slides ACM2 Slides (PDF 554 KB)

Public committee slides ACM3 Slides (PDF 677 KB)

Final scope (PDF 168 KB)

Final stakeholder list (PDF 195 KB)

Draft scope post referral (PDF 228 KB)

Draft matrix post referral (PDF 194 KB)

Equality Impact Assessment (Guidance development) - TA559 (PDF 238 KB)

Final appraisal document - TA559 (PDF 629 KB)

Committee papers - TA559 (PDF 1.06 MB)

Public committee slides - TA559 (PDF 1.65 MB)

Final appraisal document - Managed Access Agreement - TA559 (PDF 734 KB)

Appraisal consultation document (PDF version) - TA559 (PDF 583 KB)

Committee papers - TA559 (PDF 29.99 MB)

Public committee slides - TA559 (PDF 725 KB)

Public committee slides - TA559 (PDF 729 KB)

Final scope - TA559 (PDF 241 KB)

Final stakeholder list - TA559 (PDF 260 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA599 (PDF 369 KB)

Equality impact assessment (Scoping) - TA599 (PDF 220 KB)